These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

384 related articles for article (PubMed ID: 11956647)

  • 21. Cisplatin, epirubicin, and vindesine with or without lonidamine in the treatment of inoperable nonsmall cell lung carcinoma: a multicenter randomized clinical trial.
    Ianniello GP; De Cataldis G; Comella P; Scarpati MD; Maiorino A; Brancaccio L; Cioffi R; Lombardi A; Carnicelli P; Tinessa V
    Cancer; 1996 Jul; 78(1):63-9. PubMed ID: 8646728
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Concurrent versus sequential chemoradiotherapy with cisplatin and vinorelbine in locally advanced non-small cell lung cancer: a randomized study.
    Zatloukal P; Petruzelka L; Zemanova M; Havel L; Janku F; Judas L; Kubik A; Krepela E; Fiala P; Pecen L
    Lung Cancer; 2004 Oct; 46(1):87-98. PubMed ID: 15364136
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Randomized phase III study of matrix metalloproteinase inhibitor BMS-275291 in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: National Cancer Institute of Canada-Clinical Trials Group Study BR.18.
    Leighl NB; Paz-Ares L; Douillard JY; Peschel C; Arnold A; Depierre A; Santoro A; Betticher DC; Gatzemeier U; Jassem J; Crawford J; Tu D; Bezjak A; Humphrey JS; Voi M; Galbraith S; Hann K; Seymour L; Shepherd FA
    J Clin Oncol; 2005 Apr; 23(12):2831-9. PubMed ID: 15837997
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Second-line, low-dose, weekly paclitaxel in patients with stage IIIB/IV nonsmall cell lung carcinoma who fail first-line chemotherapy with carboplatin plus paclitaxel.
    Socinski MA; Schell MJ; Bakri K; Peterman A; Lee JH; Unger P; Yates S; Hudgens S; Kies MS
    Cancer; 2002 Sep; 95(6):1265-73. PubMed ID: 12216094
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Chemotherapy for advanced non-small cell lung cancer.
    Ichinose Y; Takanashi N; Yano T; Asoh H; Yokoyama H; Tayama K; Hara N; Ohta M
    Natl Med J India; 1996; 9(1):24-5. PubMed ID: 8713521
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A phase II study of recombinant human interleukin-4 for advanced or recurrent non-small cell lung cancer.
    Vokes EE; Figlin R; Hochster H; Lotze M; Rybak ME
    Cancer J Sci Am; 1998; 4(1):46-51. PubMed ID: 9467046
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A phase II study of neoadjuvant chemotherapy with cisplatin epirubicin and VP-16 for stage III unresectable non-small cell lung cancer.
    Iacobelli S; Irtelli L; Sacco R; Martino M; Mascitelli E; Basilico L; Scognamiglio M; Natoli C; Fusco O; Tinari N; Beltrami V
    Anticancer Res; 1998; 18(3B):2081-4. PubMed ID: 9677471
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Etoposide plus cisplatin followed by thoracic radiation for stage IIIB non-small cell lung cancer: MAOP study 2188.
    Lokich J; Auerbach M; Essig L; Fryer J; Fryer D
    J Infus Chemother; 1995; 5(2):70-2. PubMed ID: 8521238
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Induction chemotherapy in non small cell lung cancer stage IIIa-b and IV and second-line treatment.
    Stathopoulos GP; Dafni UG; Malamos NA; Rigatos S; Kouvatseas G; Moschopoulos N
    Anticancer Res; 1999; 19(4C):3543-8. PubMed ID: 10629650
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [An early phase II trial combining cisplatin and carboplatin in advanced non-small cell lung cancer].
    Yoshimura A; Yamano Y; Gemma A; Yoshimori K; Hayashihara K; Taniguchi Y; Uematsu K; Shibuya M; Kudoh S; Niitani H
    Gan To Kagaku Ryoho; 1993 Mar; 20(4):503-8. PubMed ID: 8383951
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Front-line chemotherapy with cisplatin and etoposide for patients with brain metastases from breast carcinoma, nonsmall cell lung carcinoma, or malignant melanoma: a prospective study.
    Franciosi V; Cocconi G; Michiara M; Di Costanzo F; Fosser V; Tonato M; Carlini P; Boni C; Di Sarra S
    Cancer; 1999 Apr; 85(7):1599-605. PubMed ID: 10193952
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Combination chemotherapy with tamoxifen, ifosfamide, epirubicin and cisplatin in extensive-disease small-cell lung cancer.
    Chen YM; Perng RP; Yang KY; Wu HW; Lin WC; Liu JM; Tsai CM; Whang-Peng J
    Zhonghua Yi Xue Za Zhi (Taipei); 2000 Aug; 63(8):605-11. PubMed ID: 10969446
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Subcutaneous interleukin-2 in combination with medroxyprogesterone acetate and antioxidants in advanced cancer responders to previous chemotherapy: phase II study evaluating clinical, quality of life, and laboratory parameters.
    Mantovani G; Madeddu C; Gramignano G; Lusso MR; Mocci M; Massa E; Ferreli L; Astara G; Macciò A; Serpe R
    J Exp Ther Oncol; 2003; 3(4):205-19. PubMed ID: 14567291
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Combined chemotherapy and differentiation therapy in the treatment of advanced non-small-cell lung cancer.
    Recchia F; Sica G; De Filippis S; Rea S; Frati L
    Anticancer Res; 1997; 17(5B):3761-5. PubMed ID: 9427776
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Carboplatin + epirubicin +VP-16 + lenograstim followed by radiotherapy + carboplatin as radiosensitizer in limited small cell lung cancer. A multicenter phase II study.
    Gridelli C; Curcio C; Iaffaioli RV; Brancaccio L; D'Aprile M; Gebbia V; Rossi A; Tortoriello A; Veltri E; Maione P; Barbarisi A; Gallo C; Guida C; Perrone F
    Anticancer Res; 2001; 21(6A):4179-83. PubMed ID: 11911315
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Neoadjuvant treatment of locally advanced carcinoma of the uterine cervix with epirubicin, paclitaxel and cisplatin.
    D'Agostino G; Distefano M; Greggi S; Salerno M; Ferrandina G; Poerio A; Mancuso S; Scambia G
    Cancer Chemother Pharmacol; 2002 Mar; 49(3):256-60. PubMed ID: 11935219
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Docetaxel-carboplatin chemotherapy combined with cetuximab in patients with locally advanced or metastatic non small-cell lung cancer (NSCLC)--results of the nonrandomised phase II study TaxErb.
    Fischer JR; Griesinger F; Fink T; Salm T; Marseille A; Wolf M
    Lung Cancer; 2012 Mar; 75(3):348-52. PubMed ID: 21908069
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Survival outcome of inoperable non-small cell lung cancer patients receiving conventional dose epirubicin and Paclitaxel as first-line treatment.
    Yang CH; Chen MC; Cheng AL; Hsu CH; Yeh KH; Yu YC; Whang-Peng J; Yang PC
    Oncology; 2005; 68(4-6):350-5. PubMed ID: 16020962
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Combination of 5-FU, high dose methotrexate, epirubicin and cisplatin (FEMTX-P protocol) in non surgical or locally recurrent metastatic gastric cancers].
    Conroy T; Wils J; Paillot B; Wagener DJ; Burghouts JT; Fickers MM; de Graeff A; Lalisang FM
    Bull Cancer; 1993 Mar; 80(3):255-60. PubMed ID: 8173178
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical and immunomodulatory effects of combination immunotherapy with low-dose interleukin 2 and tumor necrosis factor alpha in patients with advanced non-small cell lung cancer: a phase I trial.
    Yang SC; Grimm EA; Parkinson DR; Carinhas J; Fry KD; Mendiguren-Rodriguez A; Licciardello J; Owen-Schaub LB; Hong WK; Roth JA
    Cancer Res; 1991 Jul; 51(14):3669-76. PubMed ID: 1648441
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.